Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Commercial Partners

Our academic excellence in genomics and translational medicine means innovative genomic testing can advance clinical practice. 

Our fully UKAS accredited Clinical Genomics service brings the latest technology, such as the Illumina NovaSeq 6000 high throughput DNA sequencer and laboratory automation, so that we can deliver cost effective, high throughput workflows for personalised medicine. We have a number of research Next Generation Sequencing (NGS) gene panels for solid tumour and haematological malignancies and collaborate with research teams to design new panels with bespoke content, or can run whole exome sequencing. Working closely with experts in oncology at the Royal Marsden and across the North Thames GLH, we can bring novel testing through new clinical trials to patients sooner.

Our innovative genomic practice has led to successful collaborations in new clinical trials, especially in sequencing of circulating tumour DNA from liquid biopsies for colorectal cancer (TRACC), breast cancer (PEARL) and paediatric cancer (CRUK Stratified Medicine).  We have experience in delivering large national projects, such as 100,000 Genomes Project and programmes supported by Cancer Research UK include the National Lung Matrix trial for Lung and working together with the Institute of Cancer Research, we are leading in delivering genomic profiling of paediatric patients with a solid tumour.

Please contact us with your specific research requirements and for a quote.


EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib

Niamh Coleman  1 , David Woolf  2 , Liam Welsh  3 , Fiona McDonald  4 , Suzanne MacMahon  5 , Nadia Yousaf  4 , Sanjay Popat  6

Affiliations. PMID: 32981603 DOI: 10.1016/j.jtho.2020.05.006

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

Pascual J, Lim JSJ, Macpherson IRJ, Armstrong AC, Ring A, Okines AF, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Cancer Discov. 2020 Sep 21:CD-20-0553. doi: 10.1158/2159-8290.CD-20-0553. Online ahead of print. PMID: 32958578

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Gevensleben H, Cutts R, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Martin S, Wilkinson K, Moretti L, Bliss JM, Ring A. Lancet Oncol. 2020 Oct;21(10):1296-1308. doi: 10.1016/S1470-2045(20)30444-7. Epub 2020 Sep 10. PMID: 32919527 Free article. Clinical Trial.

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

doi: 10.1016/j.ejca.2019.07.027

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N. Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30. PMID: 30166348 Free PMC article. Clinical Trial.

Mason CC, Fiol CR, Baker MJ, Nadal-Melsio E, Yebra-Fernandez E, Bicalho L, Chowdhury A, Albert M, Reid AG, Claudiani S, Apperley JF, Khorashad JS. Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. Br J Haematol. 2020 Oct 6.

Dominy K, Simon IM., Sorouri-Khorashad J. Evaluation of Xpert® BCR-ABL Ultra for the confirmation of BCR-ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia. Int J Lab Hematol. 2020 Sep 29.